Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of FTC/TDF PrEP in Pregnant and Postpartum Women
NCT03386578Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of emtricitabine, tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2018; status: completed.
02
Drugs
emtricitabinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03386578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386578.